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1. Introduction 
1.1 Need for outstanding cell models for studying interwoven DNA repair pathways 
During normal human cell growth, each cell is exposed to numerous DNA-damaging 
events. DNA lesions are mainly inflicted by endogenous insults, such as normal biochemical 
activities, by-product synthesis and the in situ production of reactive oxygen species (ROS). 
DNA is also subject to genotoxic injuries resulting from diverse exogenous sources. It is not 
surprising that living organisms have evolved numerous intricate strategies to counteract 
these environmental pressures and to allow living cells to thrive in aerobic conditions. 
Through evolution various highly sophisticated pathways for protecting the genetic 
information have been retained. The first lines of defense include detoxification metabolisms 
and defense against oxidative stress. When these caretaker processes fail to insure a correct 
protection of biological molecules, such as genomic and mitochondrial DNA, DNA repair 
pathways become the ultimate bulwark against DNA damage. However, when DNA 
damage is not dealt with properly, it can adversely threaten the fidelity of the genetic 
information and ultimately lead to hereditary diseases or neoplastic processes. 
Amongst DNA lesions, DNA double-strand breaks (DSBs) are likely to be the ultimate lethal 
ones because unrepaired they can lead to chromosomal rearrangements, malignant 
transformation or apoptosis (Roos & Kaina, 2006). Endogenous DSBs mainly arise from the 
processing of single-strand breaks (SSBs) when they are converted to DSBs by DNA 
replication and/or transcription mechanisms (Mladenov & Iliakis, 2011). Given the chemical 
variety of DNA lesions encountered, evolution has retained a large diversity of DNA repair 
pathways and a tight interplay between DNA replication and DNA repair. While numerous 
DNA repair mechanisms exist, the major pathways include mismatch, excision and 
recombinational repair (Hoeijmakers, 2001) and some factors can participate in divergent 
processes. This is the case of the structure-specific endonuclease ERCC1 / XPF, which is 
required in two distinct mechanisms: excision (nucleotide excision repair or NER) and 
recombinational (single-strand annealing or SSA) repair pathways. ERCC1 / XPF 
endonuclease plays a critical role in NER by being recruited at the site of damaged DNA in 
order to cleave one strand of the damaged DNA. It is also involved in SSA, which appears to 
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be an alternative pathway to homologous recombination (HR) or nonhomologous end 
joining (NHEJ) (Al-Minawi et al., 2008). Moreover, albeit belonging to the same complex, it 
is hypothesized that ERCC1 and XPF have distinct functions in vivo because their deficiency 
can lead to different phenotypes in humans. For instance, the only patient carrying a 
mutated ERCC1 gene exhibits a cerebro-oculo-facio-skeletal syndrome with severe 
neurological defects but a moderate sensitivity to UV light and mitomycin C, the hallmark 
of XPF patients (Jaspers et al., 2007). Furthermore, there is a large body of evidence that 
raises the notion that the failure of one DNA repair pathway could modify the efficiency 
and/or fidelity of another one. An interesting example is the cross-talk between the 
mismatch repair (MMR) and recombinational pathways. MMR appears to be an essential 
mechanism for guaranteeing the fidelity of DNA replication because misincorporated 
nucleotides have to be excised immediately after DNA synthesis. Inherited defects in the 
MMR trigger a spontaneous mutation rate 50- to 1000-fold higher than that observed in 
MMR proficient cells, with a tremendous increase of spontaneous base substitution and 
frameshift mutations (for review (Iyer et al., 2006)). These mutational events could facilitate 
illegitimate recombination between nearly-homologous sequences, contributing to the onset 
of hereditary nonpolyposis colon cancer (HNPCC) (for review (Iyer et al., 2006)). Human 
MutSǂ ((Msh2-Msh6 heterodimer), and MutLǂ (Mlh1-Pms2 heterodimer) participate in the 
fidelity of genetic recombination and the suppression of gene amplification (Chen et al., 
2001). 
Another recurring theme in the DNA repair of complex genomes, such as the mammalian 
genome, is the existence of proteins with partly overlapping activities. This genetic 
redundancy appears essential for maintaining the stability of a complex genome but this 
represents a major drawback for experimental approaches designed to unravel the specific 
functions of a particular DNA repair protein. A classic example arises from the repair of 
uracil by BER. BER includes a recognition step which is performed by specific uracil-DNA 
glycosylases, following by a synthesis step conducted by the DNA polymerase beta (Pol ǃ). 
Different DNA glycosylases travel down the DNA molecule scanning for potential lesions 
(Sartori et al., 2002), and gene redundancy might make it difficult to generate uracil 
glycosylase–deficient cells because there are several genes in the mammalian genome that 
encode enzymes able to excise uracil from DNA (Pearl, 2000). Another example is the PARP 
family where PARP1 and PARP2 possess partially redundant functions as well as divergent 
activities (Menissier de Murcia et al., 2003, Schreiber et al., 2002). This functional partial 
overlap explains the survival of human cells when either the PARP1 or PARP2 gene is 
silenced (see below); in contrast double PARP1 and PARP2 knockdown leads to cell death 
(unpublished data). Fortunately, the genetic redundancy and the overlap between DNA 
repair pathways support the notion that compensating repair activities can take place over 
time. This is essential to understanding of DNA damage response (DDR)–deficient human 
cells, but also cells handled in vitro, such as knockdown cells. 
An additional point in the complex study of DNA repair factors is that several of them are 
involved in other physiological pathways, even in the absence of DNA damage. This is the 
case for certain of the NER factors and their tight relationship with the transcriptional 
machinery (Le May et al., 2010a, Le May et al., 2010b). This is also observed when different 
DNA repair pathways are key building blocks in the primary and secondary antibody 
diversification processes taking place in B lymphocytes (for review (Durandy, 2009)). 
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Actually, BER, D-NHEJ (classic DNA PKcs-dependent NHEJ), b-NHEJ (backup NHEJ), 
MMR and DNA damage signaling factors actively contribute to immunoglobulin 
diversification.  
These compelling data explain why a mutation of one DNA repair gene could trigger fetal 
or embryonic death or lead to a dramatic hereditary disorder. Human syndromes where one 
DNA repair gene is mutated have been collectively classified as “DDR-defective syndromes”. 
The range of clinical features associated with these disorders attests to the complexity of the 
DDR, its redundancy and its connection with other essential processes. That explains the 
diversity of the phenotypes observed in patients with DNA repair disorders (Table 1). It 
turned out that growing evidence demonstrates that ubiquitylation of key proteins is 
critically involved in the emergence of DDR-defective syndromes as observed for NER 
(DDB2), HR (FancD2) or TLS (PCNA). (for review (Huang & D'Andrea, 2006)). The pivotal 
role of DNA repair pathways during normal human development explains one hallmark of 
numerous DDR-defective syndromes. Actually, the main clinical features observed in 
numerous DDR-defective syndromes are hematopoietic defects (e.g. anemia or 
immunodeficiency) and neurological deficits (e.g. microcephaly), in parallel with genomic 
instability and specific DNA damage-induced sensitivities. This highlights crosslinks 
between DNA repair mechanisms and either neuronal development (O'Driscoll & Jeggo, 
2008) or immunoglobulin diversification processes (for review (Durandy, 2009)). Hence, 
numerous DDR-defective disorders exhibit microcephaly, such as LIG4 syndrome (DNA 
ligase IV gene) but also XLF-Cernunnos-SCID (XLF-Cernunnos gene), Seckel syndrome (ATR 
gene), Nijmegen breakage syndrome (NBS1 gene), Fanconi anemia (FancD1/BRCA2 gene), 
Bloom syndrome (BLM gene), Cockayne syndrome (CSA, CSB, XPB, XPD and XPG genes), 
Xeroderma pigmentosum (XPA to XPG genes), and cerebro-oculo-facio-skeletal syndrome 
(ERCC1 gene) ((Jaspers et al., 2007); for review (McKinnon, 2009, O'Driscoll & Jeggo, 2008)). 
LIG4 syndrome and XLF-Cernunnos-SCID also exhibit multiple immune abnormalities 
because both LigIV and XLF/Cernunnos are involved in the V(D)J and NHEJ pathways 
which are required during the primary repertoire of antibodies and the secondary 
diversification processes (Yan et al., 2007).  
1.2 Long term silenced human cells  
A better understanding of these hereditary disorders requires detailed insight into each 
DNA repair pathway that can operate on the damaged genome. Furthermore, the 
importance of the DDR during the multistage process leading to tumorigenesis emphasizes 
the need for outstanding biological tools to study DNA repair genes. Altogether this 
compelling evidence points to the need of outstanding cell models for unraveling the DDR 
jigsaw both for fundamental research and for the development of novel therapeutic 
strategies.  
Over the last seven years we have developed a rational strategy to silence the main DNA 
repair factors so as to unveil their functions. Since the emergence of the RNA interference 
technology, many studies have developed transient or middle-term gene silencing 
experiments targeting DDR genes, but few of them have characterized stable clones. Our 
project is based on the exceptional efficiency of pEBVsiRNA vectors in ensuring stable gene 
silencing. Our approach has been extensively described previously (Biard, 2007, Biard & 
Angulo, 2007). 
www.intechopen.com
 DNA Repair − On the Pathways to Fixing DNA Damage and Errors 
 
46
Pathways 
Diseases or 
syndromes
Mutated genes
(targeted genes*)
Main symptoms and/or remarks 
Cell cycle 
control 
Li-Fraumeni 
syndrome
p53 Sarcoma, breast, brain, leukemia 
 
familial 
retinoblastoma
Rb Retinoblastoma, osteosarcoma 
 familia melanoma p16 Melanoma, pancreas cancers 
 Sporadic cancers Chk1 
Colorectal, stomach, lung, endometrial, 
melanoma, mesothelioma cancers (for 
review (Solyom et al., 2010)) 
 
Li-Fraumeni 
syndrome
Chk2 
Breast, lung, colon, urinary, bladder, testis 
cancers, melanoma 
Signaling 
pathways 
Ataxia telangiectasia ATM 
Neurodegeneration, sterility, 
telangiectasia, dysarthria, immunological 
defects, sensitivity to IR, lymphomas 
 
ATR-Seckel 
syndrome
ATR 
Microcephaly and mental retardation, 
growth defects 
 
Ataxia telangiectasia-
like disorder 
MRE11 
Ataxia, neurodegeneration, dysarthria 
and oculomotor apraxia, mild 
immunological defects, lymphomas 
 
Familial breast cancer 
1 & 2
BRCA1, BRCA2 
Chromosome instability, sensitivity to 
DNA damage, HR deficiency, cancer 
 
Nijmegen breakage 
syndrome
NBS1 
Microcephaly, immunological defects and 
lymphoid malignacy, lymphomas 
 
NBS-like disorder 
(NBSlD)
Rad50  
DNA DSB 
repair 
LIG4 syndrome LIG4 
Microcephaly, developmental/growth 
delay, immunodeficiency and lymphomas 
 
Human 
immunodeficiency 
with microcephaly
XLF/Cernunnos Microcephaly, immunodeficiency 
 
glioblastoma (M059J 
cells)
DNAPKcs (Allalunis-Turner et al., 1993) 
 Fanconi anaemia BCRA2 
Microcephaly and medulloblastoma, Bone 
marrow and congenital defects 
DNA SSB 
repair 
Spinocerebellar 
ataxia with axonal 
neuropathy
TDP1 
Ataxia, neurodegeneration, peripheral 
axonal motor, and sensory neuropathy, 
and muscle weakness… 
 
Ataxia with 
oculomotor apraxia 1
APTX 
Ataxia, neurodegeneration, oculomotor 
apraxia and peripheral neuropathy, 
hypercholesterolaemia and 
hypoalbuminaemia 
 
cerebro-oculo-facio-
skeletal syndrome
ERCC1 
Microcephaly, moderate sensitivity to UV 
and mitomycin C (Jaspers et al., 2007) 
NER 
Xeroderma 
pigmentosum (XP)
XPA to XPG 
Neurodegeneration and microcephaly, 
UV sensitivity and skin cancer 
 
Cockayne syndrome 
(CS) 
CSA, CSB, XPB, 
XPD, XPG 
Microcephaly and dysmyelination , TCR-
specific disorder. Segmental progeria, no 
increase in cancer incidence 
 
Trichothiodystrophy 
(TDD) 
XPD, XPB, TTD-
A 
Neurodevelopmental defects and 
dysmyelination, brittle hair, nails and 
scaly skin. Segmental progeria without an 
increase in cancer incidence (Giglia-Mari 
et al., 2004)
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Pathways 
Diseases or 
syndromes
Mutated genes
(targeted genes*)
Main symptoms and/or remarks 
TLS XP variant (XP-V) XPV (pol iota) UV-induced skin cancer 
DNA cross 
link repair 
& 
Ubiquitin 
ligase 
Fanconi anaemia 
FancA, B, C, D1 
(BRCA2), D2, E, 
F, G, I, J, L, M, N
Microcephaly and medulloblastoma, 
cervical cancer, brain tumours i(FANCD2 
and FANCN), anaemia, developmental 
defects, ovarian carcinomas, head and 
neck squamous cell carcinomas, bone 
marrow failure, and myeloid leukemias. 
BER 
Multiple colorectal 
adenoma and 
carcinoma
MutYH 
DNA glycosylase involved in the repair of 
oxidative damage (Al-Tassan et al., 2002) 
 Ligase I Ligase I 
Iimmunodeficiencies and cellular 
hypersensitivity to DNA-damaging 
agents (Barnes et al., 1992) 
MMR HNPCC 
MLH1, MLH3, 
MSH2, MSH6, 
PMS2 
Hereditary nonpolyposis colon cancer, 
rectum, gastric, endometrium, ovarian, 
urinary organ cancers (Peltomaki, 2003) 
Helicase Werner syndrome WRN Severe progeria, various cancers 
 
Rothmund Thomson 
syndrome
RTS Osteosarcomas 
 Bloom syndrome BLM 
Proportional dwarfism, leukemias, 
lymphomas and others cancer 
 
Ataxia with 
oculomotor apraxia 2
SETX 
Ataxia, neurodegeneration and 
oculomotor apraxia 
(*: genes targeted with pEBVsiRNA plasmids) 
Table 1. Main DDR defective Syndromes. (Adaptated from (Hoeijmakers, 2001) and 
(McKinnon, 2009)). 
Briefly, for each gene, three pEBVsiRNA vectors are constructed and validated through both 
short-term (several days) and long-term (several weeks) experiments. Afterwards, we used 
only one “validated” vector to establish stable clones (Fig. 1). Four years ago we adopted the 
DSIR program developed by Vandenbrouck and collaborators (Vert et al., 2006) to design 
shRNA sequences. This program includes an exact similarity search algorithm for potential 
off-target detection. In a recent comparison of methods for a rational siRNA design, DSIR is 
among the three best predictive programs (Matveeva et al., 2007). Our siRNA sequences 
mainly target the open reading frame of the targeted genes, but when necessary we also use 
siRNA sequences stretching to the 3’-UTR (e.g. for rescue experiments). Among the targeted 
genes and in using our approach we have always obtained at least one vector able to impose 
long-term shut down greater than 80% as compared with control cells (as evidenced by real-
time RT-PCR).  
Using this technology, more than 160 human genes in different human cell models such as 
HeLa (Ame et al., 2009, Amine et al., 2009, Aressy et al., 2008, Betous et al., 2009, Biard, 2007, 
Biard et al., 2005, Biard & Angulo, 2007, Boehler et al., 2011, Bouley et al., 2010, Britton et al., 
2009a, Despras et al., 2007, Godon et al., 2008, Le May et al., 2010b, Ousset et al., 2010, 
Pennarun et al., 2008, Pennarun et al., 2010, Wu et al., 2007), U2OS (Betous et al., 2009, Rey et 
al., 2009) and MRC5-V1 (Bouquet et al., 2011, Britton et al., 2009b, Schmutz et al., 2010) cells 
have been silenced. Our approach has also been successfully tested in other human tumor-
derived cell lines, such as RKO (Biard & Angulo, 2007), HCT-116 (Aressy et al., 2008), Caco2 
(Coant et al., 2010), SH-SY5Y cells (Schulte et al., 2008), MCF7, MDA-MB 231, K562, UT7 
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07bd0077 07bd0077
07bd0067 07bd0067
DAPIXRCC1
07bd0071 07bd0071
07bd0073 07bd0073
XRCC1KD cells (pBD1063; day 4)
XRCC1KD cells (pBD1064; day 4)
CTL cells (day 4)
XRCC1KD cells (pBD1065; day 4)
A) Short term validation 
of 3 vectors per gene
B) Selection of clones C) Phenotypic analyses
(XRCC1 and LigIII are partners)
DAPIXRCC1
07BD289 07bd289
07bd293 07bd293
07BD295 07bd295
XRCC1KD clone 3 (day 125)
Lig3KD clone 11 (day 145)
CTL cells (day 197)
07bd200 07bd200
07bd202 07bd202
07bd206 07bd206
DAPIXRCC1
XRCC1KD clone 3
XRCC1KD clone 11
CTL cells
DAPILig3
07BD298 07bd298
07bd307 07bd307
07bd303 07bd303
XRCC1KD clone 3 (day 125)
CTL cells (day 197)
Lig3KD clone 11 (day 145)
Validation by real time PCR in comparison with CTL 
cells using GAPDH and Actin as internal controls
Lig3KD : 94%XRCC1KD : 87%
 
Fig. 1. Establishment of stable clones. 
(papers in preparation), and even in mouse NIH-3T3 cells (Meulle et al., 2008). Some authors 
have previously suggested the importance of “position-specific” criteria for efficient gene 
silencing. With the benefit of hindsight, we have never observed such a positioning effect in 
either short-term (few days) or long term (several months) experiments. In Figure 2 we show 
the position of different siRNA sequences able to impose a very efficient long-term gene 
silencing along a representative mRNA and we demonstrate no positioning effect. 
 
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
mRNA
5’ 3’
 
Fig. 2. Position of validated siRNA sequences along a representative mRNA. 
www.intechopen.com
New Insight on Entangled DNA Repair Pathways:  
Stable Silenced Human Cells for Unraveling the DDR Jigsaw 
 
49 
The maintenance of stable gene silencing for several months affords the opportunity to 
validate different siRNA sequences for an unfailing and specific gene silencing. Importantly, 
transient assays may mask the real effects of gene silencing, due to the saturation of the 
RNAi (and miRNA) machinery and by side-effects resulting from the high siRNA 
concentrations currently used. In the long-term experiments, we do not exclude the 
possibility of skews, and the suppression of gene expression over a long period may 
provoke compensatory cellular responses during an “adaptive period”. During this period, 
cellular metabolism may compensate for the decrease in protein concentration, particularly 
if the protein plays an important role in the cell. These compensating activities are also 
observed during the multistage process leading to tumorigenesis, where a normal cell 
undergoes serial genetic changes, including initiation, clonal expansion, pre-malignant 
lesions, and malignant progression, before acquiring a tumor phenotype. These properties 
acquired by cells to escape DDR defects are essential to our understanding of tumor cell 
behavior following chemo- or radiotherapy. We can now assess the usability of the 
numerous stable clones affecting all branches of the DDR that have been created. This 
unique cell model appears relevant for studying DNA repair, DNA replication, DNA 
recombination and cross-talk between them. 
To date, we have established numerous clones, creating a library of stable isogenic cells 
which no longer express a specific DNA repair gene. This approach has helped us to 
untangle the interwoven DNA repair pathways and represents a powerful tool for research, 
drug screening and for preclinical testing of new therapies. This review will concentrate on 
two fields of research investigated using these knockdown clones. 
2. Example of stable DNA repair gene silencing studies 
2.1 Dual roles of some NER factors 
NER is one of the more versatile DNA repair processes and removes diverse bulky lesions 
located on one DNA strand, including UV-induced photoproducts. In mammals, more than 
30 proteins are required for this process, which comprises first a DNA damage recognition 
and structure distortion step involving XPC-hHR23B-centrin 2 and XPE in the global 
genome (GG)-NER or RNA polymerase II in the transcription-coupled (TC)-NER. NER also 
includes the verification of lesions (XPA-RPA), strand-separating helicases (TFIIH 
containing XPB and XPD DNA helicases), structure-specific endonucleases (ERCC1-XPF and 
XPG), and the enzymes needed for gap filling (DNA polymerase ǅ/ǆ, PCNA, RFC, and 
RPA). For example, ERCC1KD and XPFKD cells exhibited a tremendous and stable decrease of 
both targeted mRNA and protein, as evidenced by real time PCR and immunofluorescence 
staining (fig. 3). Beside, as documented in the literature, the loss of one of these proteins 
induces the disappearance of the other partner. 
In GG-NER, the XPC-hHR23B-centrin 2 complex is responsible for the detection of 
damaged DNA. In TC-NER the displacement of stalled RNA polymerase complexes with 
the CSA and CSB proteins allows coordination of transcription and DNA repair. In order 
to unravel new roles for some of these gene products in this wide DNA repair network, 
we have established stable XPAKD, XPCKD, hHR23AKD, hHR23BKD, ERCC1KD and XPF KD 
HeLa cells. In the figure 4 established clones are represented for the NER and SSBR 
pathways. 
Several clones displaying undetectable protein levels of XPA or XPC were established and 
grown for more than 300 days in culture with a tremendous stability of the gene-silenced 
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07bd342 07bd342
DAPIXPF
07bd339 07bd339
07bd344 07bd344
ERCC1KD clone 11 (day 111)
CTL cells (day 197)
XPFKD clone 3 (day 62)
07bd336 07bd336
DAPIERCC1
07bd330 07bd330
07bd332 07bd332
XPFKD clone 3 (day 62)
CTL cells (day 197)
ERCC1KD clone 7 (day 111)
Validation by real time PCR in comparison with CTL 
cells using GAPDH and Actin as internal controls
XPFKD : 84%ERCC1KD : 83%  
Fig. 3. Analysis of ERCC1KD and XPFKD cells by immunofluorescence. 
and expected phenotypes (Biard et al., 2005). As expected, XPAKD and XPCKD HeLa cells 
were highly UVC sensitive and exhibited cell cycle arrest in early and middle S phase after 
UVC irradiation, showing that the persistence of UVC lesions blocks DNA replication. Both 
clones also show an impaired unscheduled DNA synthesis (UDS) after UVC irradiation. 
However, unlike XPA, the silencing of the XPC gene dramatically impeded HeLa cell 
growth. Furthermore, XPCKD HeLa clones were more sensitive to UVC than their XPAKD 
counterparts. In parallel we have analyzed the behavior of our hHR23BKD and hHR23AKD 
cells. hHR23BKD cells displayed a significant sensitivity to UVC, in contrast to their 
hHR23AKD counterparts which strongly tolerated UVC irradiation (Biard, 2007). While 
hHR23AKD cells were not blocked in S phase after UVC irradiation, the exit from the S-phase 
of hHR23BKD cells was hindered, suggesting the presence of unrepaired (or unrepairable) 
UVC-induced DNA damage. These data clearly demonstrate that hHR23A and hHR23B 
have diverse biological functions in human cells and that hHR23BKD cells have a phenotype 
closely resembling that of XPCKD cells. To understand why the silencing of the XPC gene can 
trigger major changes in cell behavior, we have performed hygromycin B withdrawal 
experiments.  
After about 200 days of culture, hygromycin B was removed from the culture medium in 
order to reverse the gene-silencing phenotype by the slow and progressive disappearance of 
pEBV episomes. Under these experimental conditions, XPA or XPC protein levels returned 
to “control” levels after 15 to 20 days in culture. Unexpectedly, reverted XPCKD cells (XPC 
re-expressing cells) did not recover a normal resistance to UVC, unlike XPAKD cells. This 
striking result suggests that irreversible genetic changes have been fixed in the genome 
during the long-term XPC gene silencing and that, beside their canonical roles, some NER 
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factors such as XPC function in other essential pathways. Whilst this can be considered to be 
a limitation of this experimental system, it allows the possibility of determining what “back-
up” systems or adaptive pathways are activated in the absence of key repair proteins.  
 
 
Fig. 4. NER versus SSBR/BER pathways. 
In the literature it is reported that in certain XP cells (e.g. XP-V), a prolonged replication 
arrest due to unrepaired UV photoproduct could trigger an early commitment to 
recombination repair pathways (Limoli et al., 2005). This alternative pathway could be 
reinforced with a deregulated p53 pathway, as observed in HeLa cells, where the HPV18 E6 
protein may degrade a part of the newly synthesized p53 protein. These data raise a 
question: are recombinational pathways altered in XPCKD cells after UVC-induced stalled 
replication forks in HeLa cells? Various reports have suggested that XPC defects elicit 
impaired cellular responses to ionizing radiation (IR), indicating a possible role of XPC in 
the cellular response to DSBs. We have sought to determine the sensitivity of NER-deficient 
cells to DSB-generating agents.  
We used our DNA PKcsKD, XRCC4KD, ligase IVKD, Rad54KD, ligase IIIKD MRE11KD, Rad50KD, 
Nbs1KD, ATMKD and ATRKD cells as controls for screening the DDR. NER-deficient HeLa 
cells were treated with either IR or etoposide (VP16), a topoisomerase II inhibitor that 
creates DSBs partly through the progression of DNA replication forks (Biard, 2007, Despras 
et al., 2007). Strikingly, XPCKD and hHR23BKD cells displayed intolerance to acute Ǆ ray 
irradiation, in contrast to their XPAKD and hHR23AKD counterparts. 24 h after high-dose 
irradiation (6 Gy) XPCKD cells, and to a lower extent hHR23BKD cells, exhibited a strong 
arrest in G2 phase as did NHEJ- and HR-deficient cells. However, using clonogenic survival 
both XPCKD and hHR23BKD cells showed a moderate sensitivity to IR (1 Gy). These data 
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suggest that beside its canonical function in the early steps of the NER, the XPC protein 
could be essential in the coordination of other recovery pathways, such as those involved in 
the repair of IR- and etoposide-induced DNA damage.  
In mock treated cells, the persistence of XPC on chromatin structures was shown by 
experiments in which the XPC protein remained tightly anchored to detergent-insoluble 
nuclear structures (Despras et al., 2007). Interestingly, XPC was released from these 
structures after induction of DSBs by calicheamicin or neocarzinostatin, two potent specific 
DSB inducers. The reduction of chromatin-fixed XPC correlated with the increase of H2AX 
phosphorylation and presumably with the recruitment of DNA repair factors at sites of 
damaged DNA. This sequence of events was partly confirmed by the subsequent 
recruitment of phosphorylated-XRCC4 and LigIV into the less extractable nuclear fraction 
after DSB induction, as previously described (Drouet et al., 2005). Therefore, XPC should be 
considered as a genome caretaker protein, which is (i) recruited for initiating the GG-NER in 
the presence of bulky DNA damage, but which (ii) also displays other functions in the 
presence of DSBs. 
Using the HeLa isogenic KD model we have also focused our attention on the efficiency of 
NER-deficient cells in performing NHEJ, using an in vitro assay making use of DNA PKcsKD 
and XRCC4KD cells. The DNA PKcsKD cells used displayed an undetectable protein level and 
a nearly total loss of the endogenous kinase activity (Despras et al., 2007), and the isolated 
XRCC4KD clones all displayed a residual XRCC4 protein level corresponding to about 15% 
of the control (CTL); this residual level might reflect the essential role played by XRCC4 in 
cell survival. These XRCC4KD cells are particularly interesting experimentally too as there 
are no human cell lines lacking the XRCC4 protein. In ligase IVKD, DNA PKcsKD and 
XRCC4KD cells, NHEJ efficiencies dropped to 50, 30 and 20%, respectively, as compared with 
control (personal data and (Despras et al., 2007)). This also correlated with a markedly 
increased sensitivity towards IR. Our results also argue for XRCC4 being a limiting factor in 
the NHEJ process, at least in vitro. Strikingly, while the expression of NHEJ factors was not 
altered in XPCKD cells, XPC deficiency led to a decrease of in vitro NHEJ efficiency. In both 
XPCKD and DNA PKcsKD cells, XRCC4 and ligase IV proteins were mobilized to damaged 
nuclear structures at lower doses of chemical DSB inducer in comparison with proficient 
cells. In contrast, XPA gene silencing did not modify HeLa cell response to DSBs. Our 
results reinforce the notion that XPCKD cells display an unexpected behavior towards DSBs, 
presumably due to an intrinsic characteristic of XPC, rather than being a consequence of 
NHEJ deficiency. We can also rule out a direct role of XPC in the NHEJ process per se. 
Presumably XPC deficiency could locally change the chromatin structure and interfere with 
other pathways. 
It is notable that in our experiments we have always observed that XPA gene silencing could 
lead to an enhanced cell growth several weeks after transfection of HeLa cells and in the 
absence of genotoxic injuries. In contrast, knocking down of XPC triggered major growth 
defects and tremendous cellular stress as well as elevated sensitivity to genotoxic agents. 
Presumably XPA and XPC can participate in major pathways required for normal growth, 
but with opposite effects. Because relationships between some NER factors and 
transcription have been extensively related in the literature (for review (Le May et al., 
2010a)), we have questioned whether XPA and XPC factors could be involved in the 
regulation of transcription in the absence of exogenous DNA damage. The transcription / 
repair factor TFIIH is organized into a core complex (XPB, XPD, p62, p52, p44, p34, and 
p8/TTDA) that associates with the Cdk-activating kinase (CAK) complex (Cdk7, cyclin H, 
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and MAT1). In response to DNA damage, XPA catalyzes the detachment of the CAK from 
the core TFIIH, changing this transcription factor into a repair factor (Coin et al., 2008). 
Thereafter, new NER proteins are recruited around the TFIIH factor such as XPC / hHR23B. 
After repair, resumption of CAK activity is required for continuation of transcription. 
By using our XPAKD, XPCKD and ERCC1KD clones, we have determined the role of these 
NER proteins during the transcriptional regulation of active promoters. Interestingly, we 
observed that the recruitment of NER factors at promoters of inducible nuclear receptor 
genes (including the retinoic acid receptors ǂ and Ǆ) occurred in a sequential order and 
required XPC, CSB, XPA / RPA, the two endonucleases, XPG and ERCC1 / XPF and XPE 
with the RNA pol II machinery (Le May et al., 2010b). This transcriptional complex 
containing NER factors is formed in the absence of any genotoxic injury, at the site of the 
promoter. Contrary to the coordinated recruitment observed in control cells, none of the 
NER factors were recruited to the promoter in XPCKD HeLa cells. XPC association is thus a 
pre-requisite step and abnormal XPC protein levels could affect normal transcription. This 
XPC-dependent transcriptional complex is distinct from a repair complex. In contrast, in 
XPAKD cells, only XPC and CSB were detected at the promoter, and in ERCC1KD cells we 
detected XPC, XPA, and XPG together with RAR, RXR, RNA pol II, and TFIIH. 
Furthermore, during the transcriptional initiation step, XPC is required to achieve optimal 
DNA demethylation and histone posttranscriptional modifications. In control cells, 
transcription initiation and recruitment of NER factors are accompanied by a global DNA 
demethylation. A local DNA demethylation at sites of 5’-CpG-3’ islands was also detected 
around the proximal RARǃ2 promoter region. In contrast, in XPCKD, XPAKD, and ERCC1KD 
HeLa cells the global methylation levels were lowered as compared with control cells. More 
importantly, XPCKD and XPAKD cells, but not ERCC1KD cells, failed to demethylate the 
RARǃ2 promoter. Afterwards, during the transcription elongation in distal regions of the 
gene, NER factors escort the RNA-Pol and form a complex which now excludes XPC but 
needs CSB. This latter complex could appear as a pre-TC-NER complex. In all of these 
studies, the phenotype of the knockdown HeLa cells was compared with that of deficient XP 
and CS fibroblasts from patients.  
Altogether these data demonstrate that NER factors could actively contribute to 
transcription of particular promoters in the absence of DNA damage and then interfere with 
cellular homeostasis. These results help us to explain the striking phenotype observed in our 
XPCKD and hHR23BKD cells in comparison with control cells or their XPAKD counterparts. 
Recently, in an effort to silence other genes belonging to the NER, we have observed that 
DDB1 gene silencing strongly disrupts HeLa cell growth a few weeks after transfection 
(unpublished data). This raises the question whether XPE (DDB2-DDB1 heterodimer) also 
participates in transcription regulation in the absence of exogenous DNA damage, as has 
been seen for XPC. 
2.2 Parp1, between inhibition and gene silencing 
We have also employed our cell model to shed light on the poly(ADP-ribose) polymerase 
(PARP) family. New developments of mono- and combined therapeutic approaches based 
on PARP inhibitors reinforce the crucial role played by these proteins in the DDR. The 
PARP family contains 17 members and its founding member, PARP1, carries out the 
majority of poly(ADP-ribose) (PAR) synthesis in mammalian cells (Ame et al., 2004, 
D'Amours et al., 2001). Poly(ADP-ribosyl)ation is an immediate DNA damage–dependent 
posttranslational modification of numerous nuclear proteins indispensable for an accurate 
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DDR. In contrast to what is frequently stated in the literature, PARP1 is not a DNA repair 
protein in stricto sensu but rather a signaling and scaffold protein which binds to DNA nicks 
and breaks in order to facilitate DNA repair by attracting other factors to damaged sites (e.g. 
XRCC1). Hence, PARP1 participates in numerous DNA repair pathways. It is a key building 
block in the SSBR, more precisely in the SPR (short patch repair) pathway, but probably in 
the first steps of the LPR (long patch repair) pathway, but not after SSB generating agents 
(see below; fig. 4). In addition, PARP1 is also involved in NER, b-NHEJ (fig. 5), 
transcription, cellular bioenergetics, telomere cohesion and mitotic segregation, centromere 
and/or kinetochore function and energy metabolism (Schreiber et al., 2006). A recent study 
shows that loss of PARP1 leads to spontaneous hyper-recombinogenic phenotype in mice, 
suggesting a balance between SSBR and HR (Claybon et al., 2010). Moreover, Patel et al. 
have observed that transient chemical inhibition of PARP1 and gene silencing interfered 
with NHEJ activities, emphasizing an interplay between the error-prone NHEJ and the 
error-free HR (Patel et al., 2011). 
We have addressed this issue by creating PARP1KD, PARP2KD, PARP3KD and PARGKD 
silenced cells (fig. 6). Our aim was to analyze spontaneous and genotoxic-induced genetic 
instability (Ame et al., 2009, Boehler et al., 2011, Godon et al., 2008). In a preliminary 
approach, we focused our attention on the requirement of PARP1 in the two SSBR pathways 
(SPR versus LPR). This approach requires the establishment of additional clones such as 
XRCC1KD, ligase IIIKD and ligase IKD cells, together with other knockdown cells which are 
presently under evaluation (Fen1KD; PNKKD, APTXKD, polǃKD).  
 
 
 
 
Fig. 5. b-NHEJ and D-NHEJ pathways. Stable knock down clones are identified as indicated 
in the legend of fig. 2. 
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Fig. 6. Characterization of PARP1KD and PARP2KD stable clones. 
This work has also been carried out to point pitfalls arising from conflicting data obtained 
after gene silencing versus chemical inhibition. Interestingly, PARP1 inhibition and gene 
silencing triggered different outcomes in terms of SSBR and radiosensitivity. Our PARP1KD 
HeLa cells display a substantial reduction in both protein and mRNA levels, with 
undetectable poly(ADP-ribose) (PAR) synthesis following exposure to H2O2 (1 mM, 10 min) 
or even after exposure to 50 Gy Ǆ rays (Godon et al., 2008). PARP1KD cells are 2.5-fold more 
radiosensitive than both controls and XRCC1KD cells, and XRCC1KD cells are 5-fold more 
sensitive to methyl methane sulfonate than their PARP1KD counterparts. PARP1 gene 
silencing prevents XRCC1-YFP recruitment at sites of local laser irradiation (405 nm), but 
does not affect the lifetime of PCNA-GFP foci, suggesting that impaired SPR (PARP1- and 
XRCC1-dependent) could be efficiently replaced by LPR (PCNA- and ligase I–dependent). 
However, we can not rule out the partial resolution of SSB by way of HR, as suggested 
elsewhere (Claybon et al., 2010). S phase–irradiated PARP1KD (and XRCC1KD) cells complete 
SSBR as rapidly as controls, while SSBR is slower in G1 cells but reaches completion. In 
contrast, PARP1 inhibition with 4-amino-1,8-naphthalimide (ANI) enhances radiosensitivity 
in highly proliferating cells (e.g. tumor cells), presumably due to the collision of unrepaired 
DNA lesions with replication forks (Noel et al., 2006). This also prevents XRCC1-YFP 
recruitment at sites of damaged DNA (laser micro-irradiation) and cells displayed a 10-fold 
slower SSBR. We also observe accumulation of huge PARP1-GFP and PCNA-GFP foci. 
These results suggest that the chemically inhibited PARP1 protein remains tethered to 
nuclear structures and that this steric hindrance impedes the recruitment of further DNA 
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repair proteins. These data emphasize that the need for careful interpretation of results from 
the use of chemical inhibitors which could be riddled with pitfalls. Moreover, it is 
noteworthy that PARP inhibitors not only inhibit PARP1, but also PARP2 and PARP3 
(Loseva et al., 2010). 
After a genotoxic injury, PARP1 activation leads to a tremendous but transient synthesis of 
PAR, in order to label DNA-damaged sites, open the chromatin structure and recruit repair 
factors, such as the scaffold protein XRCC1 (Dantzer et al., 2006). Because this reaction is 
transient, PAR polymers have to be rapidly degraded by PARG. PARP1 and PARG display 
opposite enzymatic activities which govern the balance between life and death after DNA 
injuries. Our knockdown clones clearly demonstrate that PARP1, PARP2, PARP3 and PARG 
activities contribute to this homeostasis, even in the absence of exogenous genotoxic attack 
(Ame et al., 2009, Boehler et al., 2011). PARGKD HeLa cells exhibit a stable loss of the three 
PARG isoforms (nuclear, cytoplasmic and mitochondrial) and a spectacular loss of function. 
Surprisingly, constitutive PARG depletion and subsequent PAR accumulation are rather 
beneficial in that they protect cells from spontaneous SSBs and telomeric abnormalities. In 
contrast, irradiation of PARGKD cells triggers PAR accumulation, delayed SSB and DSB 
repair, centrosome amplification and mitotic defects, all of which contribute to cell death by 
mitotic catastrophe (Ame et al., 2009). 
The complexity and the redundancy of the PARP family members toward the DDR are 
reinforced by our recent data demonstrating that PARP3 is a newcomer in the cellular 
response to DNA damage and mitotic progression (Boehler et al., 2011). PARP3 is closely 
related to PARP1 and PARP2, but unlike these two counterparts PARP3 is a mono(ADP-
ribose) polymerase. It has been proposed that PARP3 could be involved in transcriptional 
silencing in association with Polycomb group proteins. Moreover, PARP3 could also be a 
component of the DDR because it is found in complexes mainly containing Ku70 and Ku80, 
but also PARP1, DNA ligase III, DNA PKcs and DNA ligase IV (Rouleau et al., 2007). This 
raises the question whether PARP3 participates in SSBR (when PARP1 is deficient?), D-
NHEJ (with DNA PKcs, DNA ligase IV, Ku70, and Ku80), b-NHEJ (with DNA ligase III) and 
telomere maintenance (with Ku70 and Ku80). This was partly confirmed by a recent study 
which shows that PARP3 might be a novel DSB sensor which functions in the same pathway 
as APLF (aprataxin- and PNK-like factor) in order to accelerate chromosomal DSB repair 
(Rulten et al., 2011). APLF is a poly(ADP-ribose)-binding protein which interacts directly 
with Ku80 and XRCC4 at sites of DSBs (Macrae et al., 2008). To gain further insight into 
PARP3 function in the DDR we have validated pEBVsiPARP3 plasmids targeting the two 
known PARP3 isoforms. Stable clones exhibiting an almost complete depletion of PARP3 
were carefully characterized (Boehler et al., 2011). PARP3KD cells displayed spontaneous 
DSBs and genome instability, delayed repair after irradiation, but no significant 
radiosensitivity as compared with control cells. Our results reinforce recent data showing 
that PARP3-deficient cells were as sensitive to a topoisomerase I poison (camptothecin) as 
control cells (Loseva et al., 2010). These unexpected results could be explained by partly 
compensating activities between PARP3 and PARP1. These data strongly suggest a 
functional synergistic cross-talk between PARP1 and PARP3. Interestingly, PARP3 interacts 
directly and strongly with PARP1 and PARP3 is able to activate PARP1 in the absence of 
DNA (Loseva et al., 2010). Another significant event observed in PARP3KD cells is an 
elevated frequency of sister telomere fusions and sister telomere loss. This is explained by 
the functional association between PARP3, tankyrase I and NuMa (microtubule-associated 
protein involved in spindle dynamics). Altogether, these three proteins appear to be key 
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regulators of mitotic progression. This study will now continue by establishing new cell 
lines silenced for other members of the PARP family such as PARP9, PARP14, tankyrase 1 
(PARP5a) and tankyrase 2 (PARP5b). 
3. Conclusions 
In the field of cancer research, numerous questions remain unanswered, such as how do 
different pathways cooperate to repair DNA damage in tumor cells? How can we explain 
the chemo- and radioresistance of tumor cells? Can we target DDR to enhance 
chemotherapy? How do genetic compensation events take place? How can we detect the 
combinations of genes leading to synthetic lethality? Are DNA repair factors involved in 
other processes? All of these questions have to be carefully analyzed in order to design 
specific and less toxic therapies for cancer. Currently, chemotherapeutic approaches are 
based on the fact that highly proliferating (tumor and unfortunately hair, bone marrow and 
colon) cells are more sensitive to DNA damage than their slowly proliferating (normal) 
counterparts. Alterations in DNA repair pathways in tumor cells can make some cancer cells 
dependent on a reduced set of DNA repair pathways for their survival. These adaptive but 
potentially error-prone bypasses could render DNA damage–based cancer therapies less 
efficient and allow tumor cells to escape specific treatments. Recently substantial progress 
has been made through studies of genes involved in the DDR in order to circumvent rescue 
pathways. A breakthrough has emerged with the concept of synthetic lethality, which is 
defined as a genetic interaction where the minimal combination of two nonlethal mutations 
leads to cell death. Because naturally occurring synthetic lethal mutants are unviable we 
have to develop outstanding cell models in order to unravel the DDR and subsequently to 
detect these combinations that give rise to synthetic lethality. In light of these concerns, an 
emerging strategy has been to use PARP inhibitors (e.g. iniparib, olaparib or veliparib) 
combined or not with DNA-damaging chemotherapeutic agents in the treatment of breast 
and ovarian cancers exhibiting germ-line mutations in BRCA genes (Bryant et al., 2005, 
Farmer et al., 2005, Mullan et al., 2006). Because of the partial redundancy between BRCA 
functions, PARP inhibitors have to be administered to patients displaying loss of copies of 
both the BRCA1 and BRCA2 (FancD1) genes. This approach is based on compelling evidence 
demonstrating why BRCA1 and 2 act as molecular determinants in the response to 
chemotherapeutic agents (Quinn et al., 2003). Amongst prominent defects observed in 
BRCA1/2-deficient tumor cells, aberrant G2/M checkpoint control and impaired DNA 
repair (HR) modulate sensitivity to genotoxic agents (Hartman & Ford, 2002, Moynahan et 
al., 1999). Interestingly, BRCA1 also participates in GG-NER (but not TC-NER) in a p53-
independent manner by inducing the expression of XPC, DDB2 (XPE), and GADD45 
(Hartman & Ford, 2003). In tumor cells, compensating repair activities taking place during 
clonal expansion could compensate HR (and GG-NER) deficiencies with other DNA repair 
pathways, such as those dependent on PARP1 (SSBR or b-NHEJ). In these conditions, PARP 
inhibition might lead to the persistence of DNA lesions normally repaired by HR and trigger 
tumor cell death without affecting normal cells (Farmer et al., 2005). Other genetic defects 
could lead to synthetic lethality associated with PARP inhibition, such as impaired PTEN 
(phosphatase and tensin homolog) (Mendes-Pereira et al., 2009), Fanconi anemia genes 
(D'Andrea, 2010) or ATM (Williamson et al., 2010) genes. Now, this approach has been 
enlarged to metastatic triple-negative breast cancers having inherent defects in DNA repair 
(O'Shaughnessy et al., 2011). Interestingly, a recent paper shows that PARP inhibition could 
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also interfere with the NHEJ pathways in that PARP inactivation in HR-deficient cells 
enhances NHEJ activities (Patel et al., 2011). We have to keep in mind that, in mammalian 
cells, the high-speed 'classic' DNA-PKcs–dependent NHEJ (D-NHEJ) pathway repairs 
general DSBs. While some DNA ends may be rapidly joined through the D-NHEJ, other 
breaks are processed for homology searches. These ends may be substrates for the 
alternative low-speed backup NHEJ (b-NHEJ, also termed microhomology-based end-joining 
pathway) involving ligase III, XRCC1 and PARP1 (Audebert et al., 2006, Iliakis et al., 2004, 
Verkaik et al., 2002, Wang et al., 2006). Hence, this raises the question whether PARP1 
inactivation induces NHEJ compensation due to impaired HR function or b-NHEJ function 
or both. To strengthen this notion we have observed that NHEJ activities were enhanced in 
ligase IIIKD HeLa cells when the b-NHEJ was expected to be hampered (as well as BER) 
(unpublished data). Altogether this striking example clearly highlights the requirement to 
study the interwoven DNA repair pathways in tumor cells using a relevant cell model. Now 
we are seeking to evaluate the compensating activities between different pathways, such as 
D-NHEJ versus b-NHEJ or HR versus D-NHEJ. We have also established TLS-deficient clones 
in order to determine the role of specialized (TLS) DNA polymerases in the absence of DNA 
injuries (fig. 7). Our published results show that these polymerases facilitate the progression 
of the replication fork through external replication barriers (e.g. bulky adducts) and also 
through naturally occurring DNA structures (G4 structures, H-DNA or Z-DNA). More 
precisely, Pol η and Pol κ help to prevent genomic instability occurring at such natural DNA 
sequences (Betous et al., 2009). Pol η also maintains chromosomal stability and prevents 
common fragile site breakage during unperturbed S phase (Rey et al., 2009). 
 
 
Fig. 7. TLS and MMR pathways. Stable knock down clones are identified as indicated in the 
legend of fig. 3. 
www.intechopen.com
New Insight on Entangled DNA Repair Pathways:  
Stable Silenced Human Cells for Unraveling the DDR Jigsaw 
 
59 
To conclude, the major advantage of this strategy is the rapid establishment of new stable 
knockdown clones in various tumor-derived cells, which display stable gene silencing. A 
recent development has been to create dual pEBVsiRNA plasmids allowing efficient 
knockdown of two or more genes. For instance, double knockdown cells have been created 
where both DNA PKcs and ligase III were efficiently silenced with a single pEBVsiRNA 
vector. These cells, which grow normally, are expected to be deficient for both D-NHEJ and 
b-NHEJ. We have also developed plasmids targeting an endogenous gene and re-expressing 
an exogenous transcript carrying functional mutations. The latter approach allows mutant 
cells to be generated when the loss of the targeted gene is lethal. Hence, because we can 
easily and efficiently create DDR-deficient cells where one or more genes are silenced, we 
are now able to unravel the spectacular network of DNA repair pathways. 
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